Table 1.
Baseline characteristics of the subjects with type 2 diabetes at study enrollment
| Parameter | Patients (n = 22) |
|---|---|
| Age (years) | 68.0 ± 9.9 |
| Male, n (%) | 15 (68) |
| BMI (kg/m2) | 23.9 [22.8, 25.4] |
| Duration of diabetes (years) | 18.6 ± 9.2 |
| Duration of insulin therapy (years) | 9.2 ± 5.9 |
| HbA1c (%) | 7.7 ± 0.6 |
| Fasting plasma glucose (mg/dL) | 145.2 ± 24.3 |
| Fasting serum C-peptide (ng/mL) | 1.18 [0.85, 1.58] |
| eGFR (mL/min/1.73 m2) | 61.8 ± 15.0 |
| Diabetic complications, n (%) | |
| Retinopathy | 5 (23) |
| Nephropathy | 7 (32) |
| Neuropathy | 8 (36) |
| Prior premixed insulin, n (%) | |
| BHI30 | 12 (55) |
| BIAsp30 | 10 (45) |
| Oral antidiabetic agents, n (%) | |
| Sulfonylurea | 1 (5) |
| Metformin | 4 (18) |
| αGI | 3 (14) |
| DPP-4 inhibitor | 10 (46) |
| SGLT-2 inhibitor | 1 (5) |
| Statins, n (%) | 13 (59) |
Data are presented as means ± SD, median and interquartile ranges, or n (%)
BMI body mass index, HbA1c glycated hemoglobin, eGFR estimated glomerular filtration rate, BHI30 human insulin 30%/neutral protamine Hagedorn insulin 70%, BIAsp30 insulin aspart 30%/protaminated insulin aspart 70%, αGI α-glucosidase inhibitor, DPP-4 dipeptidyl peptidase-4, SGLT-2 sodium glucose cotransporter-2